What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @drdavidliew: For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunog

      David Liew drdavidliew

      4 years ago
      For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx
      RT @RHEUMarampa: Factors associated w/ poor COVID19 outcomes in #SLE from the GRA @rheum_covid
      📌Demographics - age,

      sheila RHEUMarampa

      4 years ago
      Factors associated w/ poor COVID19 outcomes in #SLE from the GRA @rheum_covid 📌Demographics - age, sex, region 📌Glucocorticoid use 📌 Comorbids - renal, CV 📌Untreated/active dse ❗Very important msg here: Control dse, manage comorbids & avoid GCs @RheumNow #ACR21 abs0866 https://t.co/eXR3KqGrJa
      RT @KDAO2011: Dr. Thomas reviews risk for progression to RA
      👉+ACPA (9% risk)
      👉1st

      TheDaoIndex KDAO2011

      4 years ago
      Dr. Thomas reviews risk for progression to RA 👉+ACPA (9% risk) 👉1st degree relative 3-9X risk 👉70% risk in 5 years of both are true!👈 #ACR21 @rheumnow https://t.co/y5eUyacBFT
      RT @synovialjoints: Radiographic progression in AS is greatest between ages 30-39. The presence of preexisting structura

      Dr. Antoni Chan synovialjoints

      4 years ago
      Radiographic progression in AS is greatest between ages 30-39. The presence of preexisting structural damage starts to accelerate it from earlier ages. Data from 1125 patients followed from 2001-2018 @RheumNow #ACR21 Abst#0897 https://t.co/g0t45R0lOd https://t.co/RvlO9EcMIX
      RT @RichardPAConway: 3 year results of SELECT-COMPARE study of upadacitinib. No evidence of a signal in cardiovascular e

      Richard Conway RichardPAConway

      4 years ago
      3 year results of SELECT-COMPARE study of upadacitinib. No evidence of a signal in cardiovascular events or cancer. Reassuring, but really need an ORAL-Surveillance style study of upadacitinib to be confident. Abstr#0828 #ACR21 @RheumNow
      RT @AurelieRheumo: An important message from Dr Ranjeny Thomas on #RA #disease control: "Patients can have a significant

      Aurelie Najm AurelieRheumo

      4 years ago
      An important message from Dr Ranjeny Thomas on #RA #disease control: "Patients can have a significant impact on the control of their disease, and the interventions we recommend need to be personalised to their resilience ability." #ACR21 @RheumNow https://t.co/h63uz5kfU8
      RT @doctorRBC: Gender differences in secukinumab treatment of AS?
      ⭐️improved disease activity, global function, depr

      Robert B Chao, MD doctorRBC

      4 years ago
      Gender differences in secukinumab treatment of AS? ⭐️improved disease activity, global function, depression in men and women ⭐️women ⬆️disease burden ⭐️high retention rates irrespective of gender Abs#909 #ACR21 @RheumNow https://t.co/L6mCxuSMo1 https://t.co/pR3OBoXqaT
      RT @drdavidliew: Booking regular clinic visits for controlled RA pts - can we be more efficient?

      12m RCT
      Self-monitorin

      David Liew drdavidliew

      4 years ago
      Booking regular clinic visits for controlled RA pts - can we be more efficient? 12m RCT Self-monitoring app, supported self-initiated care only one scheduled follow-up visit controlled RA pts DAS28/pt satisfaction same visits/y: 1.7 vs 3.0 @reade_020 #ACR21 ABST0830 @RheumNow https://t.co/600XTKo9GM
      RT @KDAO2011: Risks for RA:
      - chromosome 6 has HLA risk genes encoding HLA-I and -II
      - HLA-DRB1 *04:01 and *04:04 stonrg

      TheDaoIndex KDAO2011

      4 years ago
      Risks for RA: - chromosome 6 has HLA risk genes encoding HLA-I and -II - HLA-DRB1 *04:01 and *04:04 stonrgly assc w/ RA in white Americans/Europeans - the Shared epitope increase risk for RA & severe disease; high assc with ACPA+ Protective➡️HLA-DRB1*13:01 @rheumnow #ACR21 2/2
      RT @KDAO2011: Chances for RA if a family member has RA?
      Dr. B Masri reviews familial studies:
      👉person w/1st degree

      TheDaoIndex KDAO2011

      4 years ago
      Chances for RA if a family member has RA? Dr. B Masri reviews familial studies: 👉person w/1st degree relative w/ RA has 2-4 X risk 👉Multigen study standard incidence ratios: 3.02 child, 4.64 siblings, 9.31 in multiplex family, 6.48 twins, 1.17 in spouses #ACR21 @rheumnow 1/
      RT @KDAO2011: Dr. Ranjeny Thomas on preventing RA:
      👉60% genetics/immunopathogenesis (noncontrollable factors)
      👉40%

      TheDaoIndex KDAO2011

      4 years ago
      Dr. Ranjeny Thomas on preventing RA: 👉60% genetics/immunopathogenesis (noncontrollable factors) 👉40% lifestyle modifications: healthy diet, healthy weight, avoiding tobacco, reduce occupational exposure, improve exercise/sleep, decrease stress. #ACR21 @rheumnow 1/2 https://t.co/eoh3kcekR8
      RT @Yuz6Yusof: Don't forget to catch up with our @RheumNow Faculty Panel discussion on What's Hot and Not Daily Recap fo

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      Don't forget to catch up with our @RheumNow Faculty Panel discussion on What's Hot and Not Daily Recap for Saturday #ACR21 @RichardPAConway @AurelieRheumo @bella_mehta @_Castillo_Pedro https://t.co/x2xu6k2h9x
      RT @AurelieRheumo: MTX and liver: FibroScan scores compatible with liver fibrosis are significantly correlated w/ severa

      Aurelie Najm AurelieRheumo

      4 years ago
      MTX and liver: FibroScan scores compatible with liver fibrosis are significantly correlated w/ several parameters -BMI -waist circumference -male gender -age but NOT MTX cumulative dose in a cohort of 500+ patients. #Abst0786 @RheumNow #ACR21 https://t.co/RkSpVqN4qF https://t.co/9TENaR0WZ3
      RT @doctorRBC: Drug retention of TNFi vs. secukinumab in AxSpA pts
      Abs#911
      ⭐️46% discontinued either treatment
      ⭐ï

      Robert B Chao, MD doctorRBC

      4 years ago
      Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX
      RT @swethaann23: Detecting inflammation in SIJ for axSpA is by MRI but Artificial intelligence convolutional network aid

      swethaann23 swethaann23

      4 years ago
      Detecting inflammation in SIJ for axSpA is by MRI but Artificial intelligence convolutional network aids this: -In the Validation set: Trained CNN ▶️91.8% accuracy; Sens 88.9% Sp 93.5% - Holdout set: 81.5% accuracy; Sens 67%; Sp 84.5%. Abst# 0905 #ACR21 #ACRBest @RheumNow https://t.co/qmOxk9JQOC

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×